How the NeoGenomics PTEN IHC test supports targeted prostate cancer treatment
NeoGenomics launches an FDA-approved PTEN IHC companion diagnostic to identify prostate cancer patients eligible for AstraZeneca’s Truqap.
Medical Devices & Diagnostics
Pharma & Biotech
Otsuka’s Astex secures $515m Roche deal for cell-cycle breast cancer candidates
Discover why Roche and Otsuka-owned Astex are pursuing a $515 million cell-cycle breast cancer programme and what risks remain.
Medical Devices & Diagnostics
Why AstraZeneca’s Truqap win could force a new testing era in prostate cancer
Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.
Pharma & Biotech
Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations
Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?
Pharma & Biotech
ASCO 2026: Menarini’s elacestrant program expands the fight against endocrine resistance
Find out how Menarini’s elacestrant data at ASCO 2026 could reshape ER-positive metastatic breast cancer treatment.
Pharma & Biotech
Why AstraZeneca’s TRUQAP ODAC vote could reshape PTEN-deficient prostate cancer treatment
TRUQAP has ODAC support, but toxicity and survival maturity still matter. AstraZeneca’s prostate cancer expansion now faces FDA’s final test.